This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| ceftriaxone | |
|---|---|
| Name | Ceftriaxone |
| Caption | Structural formula of ceftriaxone |
| Tradename | Rocephin, others |
| Routes | Intravenous, intramuscular |
| Class | Third-generation cephalosporin |
| Metabolism | Minimal hepatic |
| Elimination | Renal and biliary |
| Cas number | 104376-79-6 |
ceftriaxone
Ceftriaxone is a third-generation cephalosporin antibiotic used to treat a wide range of bacterial infections. It is administered by intravenous or intramuscular injection and is widely used in hospitals and outpatient settings for indications from community-acquired infections to severe nosocomial diseases. Major global health organizations and national formularies list ceftriaxone among essential antimicrobials endorsed for specific indications by public health authorities and infectious disease societies.
Ceftriaxone is indicated for treatment of meningitis associated with pathogens recognized by the World Health Organization, severe pneumonia cited in guidelines from the Centers for Disease Control and Prevention, complicated urinary tract infections described in recommendations by the National Institute for Health and Care Excellence, and gonorrhea treated per guidance from the World Health Organization. It is also used for intra-abdominal infections referenced in surgical protocols at institutions such as the American College of Surgeons and for Lyme disease manifestations outlined by the Infectious Diseases Society of America. In obstetrics and neonatology, ceftriaxone appears in prophylaxis schemes related to delivery settings described by the Royal College of Obstetricians and Gynaecologists and in management pathways aligned with UNICEF-supported perinatal programs.
Reported adverse effects include hypersensitivity reactions documented in allergy reviews associated with the American Academy of Allergy, Asthma & Immunology and hematologic abnormalities discussed in publications from the American Society of Hematology. Biliary sludging and gallbladder pseudolithiasis have been reported in case series published through journals linked to the American Gastroenterological Association. Neurologic complications in renal impairment and local injection-site reactions have been reviewed in clinical toxicology reports affiliated with the Food and Drug Administration and the European Medicines Agency. Post-marketing surveillance coordinated by national pharmacovigilance centers such as those in Japan, Canada, and Australia records rare hepatic and renal adverse events.
Ceftriaxone exerts bactericidal activity by binding to penicillin-binding proteins characterized in structural studies connected to research at institutions like the Pasteur Institute and the Max Planck Institute. Binding inhibits peptidoglycan cross-linking in bacterial cell walls, a mechanism elucidated in biochemical investigations cited by the Royal Society and academic groups at Johns Hopkins University and Harvard Medical School. The drug’s affinity for specific transpeptidases is discussed in molecular microbiology literature associated with the Wellcome Trust and the Howard Hughes Medical Institute. Interaction studies referencing the European Molecular Biology Laboratory describe how cell wall synthesis inhibition leads to osmotic lysis in susceptible organisms.
Pharmacokinetic profiles of ceftriaxone include high plasma protein binding and prolonged half-life allowing once-daily dosing regimens used in clinical trials sponsored by institutions such as the National Institutes of Health. Dual elimination via renal excretion and biliary secretion is described in pharmacology texts associated with Oxford University Press and Elsevier clinical handbooks. Studies performed at hospitals affiliated with the Mayo Clinic and Cleveland Clinic examined cerebrospinal fluid penetration in meningitis, while population pharmacokinetic modeling work from Imperial College London addresses dosing adjustments in hepatic or renal dysfunction. Drug interaction alerts have been issued in formularies maintained by the British National Formulary and the Australian Therapeutic Goods Administration.
Ceftriaxone has activity against many Gram-negative and some Gram-positive pathogens, with coverage profiles summarized in susceptibility reports from the European Centre for Disease Prevention and Control, the Centers for Disease Control and Prevention, and the World Health Organization. Resistance mechanisms including extended-spectrum beta-lactamases and carbapenemase emergence are documented in surveillance networks such as the Global Antimicrobial Resistance Surveillance System and in research centers like the Pasteur Institute and the Wellcome Sanger Institute. Clinical microbiology guidelines from the Clinical and Laboratory Standards Institute and the European Committee on Antimicrobial Susceptibility Testing provide breakpoint recommendations reflecting resistance trends reported by academic centers including Stanford University and the University of Tokyo.
Recommended dosing regimens—ranging from once-daily intravenous doses in community-acquired infections to higher-frequency regimens in severe sepsis—appear in clinical practice guidelines issued by the Infectious Diseases Society of America, the Surviving Sepsis Campaign, and national health services such as NHS England. Intramuscular injection technique and preparation guidance are included in procedural manuals used in emergency medicine departments at Mount Sinai Hospital and Massachusetts General Hospital. Pediatric dosing and neonatal considerations are discussed in pediatric formularies from the American Academy of Pediatrics and the European Society for Paediatric Infectious Diseases. Storage and reconstitution recommendations are provided in compendia published by the United States Pharmacopeia and the Japanese Pharmacopoeia.
Ceftriaxone was developed and introduced into clinical practice in the 1980s, with pharmaceutical development and regulatory approval processes involving companies and agencies such as Hoffmann-La Roche, the Food and Drug Administration, and the European Medicines Agency. Its adoption influenced treatment protocols in hospitals affiliated with universities including Yale and Columbia and played roles in public health responses to outbreaks covered by media outlets like the BBC and The New York Times. Debates on antimicrobial stewardship involving bodies such as the World Health Organization, the Centers for Disease Control and Prevention, and national ministries of health reflect societal concerns about resistance and access, while global initiatives from the Bill & Melinda Gates Foundation and the Wellcome Trust address research and distribution challenges.
Category:Cephalosporin antibiotics